FDA leadership faces potential overhaul while new treatments advance for stroke prevention, muscular dystrophy, and weight management, alongside emerging infectious disease and diagnostic innovations.

The White House has signed off on plans to fire FDA Commissioner Marty Makary, according to sources familiar with the matter, marking a significant leadership change at the regulatory agency.

Factor XIa inhibitor asundexian demonstrated benefits beyond stroke prevention in the OCEANIC-STROKE trial, reducing recurrent ischemic stroke risk and severity when strokes do occur.

NICE recommended givinostat for all types of Duchenne Muscular Dystrophy, potentially offering around 530 patients a drug that may delay disease progression by up to 5 years.

WHO officials are rapidly developing guidance protocols as a cruise ship with a hantavirus outbreak heads toward Tenerife, marking the first documented ship-borne outbreak of the disease.

Gastric sleeve endoscopy continued producing significant weight loss after GLP-1 therapy cessation, showing greater total weight loss compared to lifestyle modification alone at 1-year follow-up.

Researchers integrated multiple genetic risk scores to improve prediction of eight cardiovascular conditions, enhancing the performance of existing clinical risk-assessment tools.

A new blood test measuring basophil activation markers identified sesame seed allergy in children more accurately than traditional skin prick tests and standard blood tests.

Early antiviral prophylaxis with oseltamivir reduced nursing home hospitalizations when administered to 70% or more of residents within 48 hours of outbreak detection, though German logistics may complicate rapid implementation.